Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate
- 31 July 2004
- journal article
- Published by Elsevier BV in Experimental Neurology
- Vol. 188 (1), 128-138
- https://doi.org/10.1016/j.expneurol.2004.03.022
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor functionNature Medicine, 2003
- Initial agonist treatment of Parkinson diseaseNeurology, 2003
- Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian modelsNeurology, 2001
- Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson’s diseaseThe FASEB Journal, 2001
- Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeysMovement Disorders, 1998
- Dopaminergic Neurons Intrinsic to the Primate StriatumJournal of Neuroscience, 1997
- A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Lesion of the subthalamic nucleus for the alleviation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in the primateMovement Disorders, 1991
- Reversal of Experimental Parkinsonism by Lesions of the Subthalamic NucleusScience, 1990
- Chronic treatment withl-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone bindingBrain Research, 1986